Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Equity Ratio (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Equity Ratio readings, the most recent being 0.7 for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 0.86% to 0.7 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.7, a 0.86% increase, with the full-year FY2025 number at 0.7, up 0.86% from a year prior.
  • Equity Ratio hit 0.7 in Q4 2025 for Neurocrine Biosciences, roughly flat from 0.7 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.77 in Q3 2024 to a low of 0.65 in Q1 2022.
  • Median Equity Ratio over the past 5 years was 0.7 (2024), compared with a mean of 0.7.
  • Biggest five-year swings in Equity Ratio: increased 26.98% in 2021 and later decreased 8.77% in 2025.
  • Neurocrine Biosciences' Equity Ratio stood at 0.66 in 2021, then grew by 8.75% to 0.72 in 2022, then fell by 4.79% to 0.69 in 2023, then rose by 1.45% to 0.7 in 2024, then increased by 0.86% to 0.7 in 2025.
  • The last three reported values for Equity Ratio were 0.7 (Q4 2025), 0.7 (Q3 2025), and 0.69 (Q2 2025) per Business Quant data.